Alzheimer's disease: New protective protein SORLA and gene APOE2 show therapeutic promise

Researchers at the Sanford Burnham Prebys Center in California reported that raising levels of the brain‑specific protein SORLA markedly reduces toxic tau‑protein aggregates and prevents neurodegeneration in genetically modified mice. The study, published in Science Advances, showed that higher SORLA curbed tau hyperphosphorylation, limited the spread of abnormal tau, and protected brain size and function.

In a separate investigation, scientists at the Buck Institute for Research on Aging identified the rare APOE2 allele as a protective factor that helps brain cells repair DNA damage and avoid cellular senescence. Using human induced pluripotent stem cells and mouse brain tissue, they found neurons carrying APOE2 accumulated less DNA damage and recovered faster from stress than those with APOE3 or the high‑risk APOE4 variant. The findings, reported in Science Daily, suggest that therapies mimicking APOE2 could bolster neuronal genome defenses and slow brain aging.

Both discoveries point to new avenues for Alzheimer’s treatment by targeting protein‑based and genetic mechanisms that shield neurons from degeneration.